A Moment Of Truth For Biogen’s Alzheimer’s Drug – And The Biotech Sector
As the deadline for the FDA to decide whether to approve it nears, Biogen’s much-debated Alzheimer’s drug aducanumab faces its moment of truth – and… Read More »A Moment Of Truth For Biogen’s Alzheimer’s Drug – And The Biotech Sector